Mina Noura
Overview
Explore the profile of Mina Noura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamada C, Okada K, Odaira K, Tokoro M, Iwamoto E, Sanada M, et al.
Cancer Med
. 2024 Jul;
13(14):e7471.
PMID: 39015025
Background: ZNF384-fusion (Z-fusion) genes were recently identified in B-cell acute lymphoblastic leukemia (B-ALL) and are frequent in Japanese adult patients. The frequency is about 20% in those with Philadelphia chromosome-negative...
2.
Noura M, Tomita S, Yasuda T, Tsuzuki S, Kiyoi H, Hayakawa F
Cancer Med
. 2024 Jun;
13(13):e7445.
PMID: 38940430
Introduction: Nucleoporin 98 (NUP98) fusion proteins are recurrently found in leukemia and are associated with unfavorable clinical outcomes. They are distributed to the nucleus and contribute to leukemogenesis via aberrant...
3.
Matsuo H, Inagami A, Ito Y, Ito N, Iyoda S, Harata Y, et al.
Commun Biol
. 2024 Jan;
7(1):123.
PMID: 38267545
Acute myeloid leukemia (AML) is a malignancy characterized by differentiation arrest of hematopoietic precursor cells. Differentiation therapy is effective for patients with acute promyelocytic leukemia; however, only a few effective...
4.
Noura M, Matsuo H, Yasuda T, Tsuzuki S, Kiyoi H, Hayakawa F
Oncogene
. 2023 Dec;
43(6):447-456.
PMID: 38102337
TAL1 is one of the most frequently dysregulated genes in T-ALL and is overexpressed in about 50% of T-ALL cases. One of the molecular mechanisms of TAL1 overexpression is abnormal...
5.
Kojima Y, Kawashima F, Yasuda T, Odaira K, Inagaki Y, Yamada C, et al.
Int J Hematol
. 2023 May;
118(1):65-74.
PMID: 37149540
Gene aberrations of B-cell regulators and growth signal components such as the JAK-STAT pathway are frequently found in B-cell acute lymphoblastic leukemia (B-ALL). EBF1 is a B-cell regulator that regulates...
6.
Mikami M, Masuda T, Kanatani T, Noura M, Umeda K, Hiramatsu H, et al.
Mol Cells
. 2022 Dec;
45(12):886-895.
PMID: 36572559
Malignant rhabdoid tumor (MRT) is a highly aggressive pediatric malignancy with no effective therapy. Therefore, it is necessary to identify a target for the development of novel molecule-targeting therapeutic agents....
7.
Odaira K, Yasuda T, Okada K, Shimooka T, Kojima Y, Noura M, et al.
Cancer Sci
. 2022 Nov;
114(3):781-792.
PMID: 36341510
CEBPA-IGH, a fusion gene of the immunoglobulin heavy-chain locus (IGH) and the CCAAT enhancer-binding protein α (C/EBPα) gene, is recurrently found in B-ALL cases and causes aberrant expression of C/EBPα,...
8.
Kubota H, Masuda T, Noura M, Furuichi K, Matsuo H, Hirata M, et al.
EJHaem
. 2022 Jul;
2(3):449-458.
PMID: 35844683
Patients with refractory graft-versus-host disease (GVHD) have a dismal prognosis. Therefore, novel therapeutic targets are still needed to be identified. Runt-related transcriptional factor (RUNX) family transcription factors are essential transcription...
9.
Matsuo H, Nakatani K, Harata Y, Higashitani M, Ito Y, Inagami A, et al.
Biochem Biophys Rep
. 2021 Aug;
27:101099.
PMID: 34430715
One of the most frequent cytogenetic abnormalities in acute myeloid leukemia (AML) is t(8;21). Although patients with t(8;21) AML have a more favorable prognosis than other cytogenetic subgroups, relapse is...
10.
Noura M, Morita K, Kiyose H, Okuno Y, Matsuo H, Koyama A, et al.
Br J Haematol
. 2021 Jul;
194(3):598-603.
PMID: 34227104
Differentiation therapy is a less toxic but still a very effective treatment for a subset of acute myeloid leukaemia (AML) cases. With the goal to identify novel compounds that can...